Hormone therapy showdown: can dydrogesterone tame teen irregular periods?
NCT ID NCT07703488
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study looks at whether dydrogesterone, a hormone pill, works better than a common birth control pill (drospirenone and ethinylestradiol) for treating irregular, heavy, or prolonged periods in teenagers aged 10 to 19. The main goal is to see how many teens have normal cycles after six months of treatment. Researchers will also track side effects, bleeding patterns, and quality of life. The findings could help doctors choose the best hormone therapy for young people with ovulation-related bleeding problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dydrogesterone
- What this could lead to
- If successful, this could show that dydrogesterone is a safe and effective option for managing irregular periods in teenagers, potentially improving long-term cycle control and quality of life.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be less reliable. The small sample size and short follow-up may limit how broadly the findings apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABNORMAL UTERINE BLEEDING (AUB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Women and Children Hospital
RECRUITINGGuangzhou, Guangong, 511400, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.